Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem LutaPol/ItraPol (177Lu/90Y-DOTATATE) for Neuroendocrine Neoplasms
2024-516503-17-01Phase 3Authorised
- Sponsor
- National Centre for Nuclear Research
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of DuoNEN in apudoma (NET), sponsored by National Centre for Nuclear Research. Primary endpoint: Disease progression by RECIST 1.1. Planned start Jan 2025; status: authorised.
02
Drugs
DuoNEN
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2024-516503-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516503-17-01.